从生物标志物到神经退行性疾病的精准医学：我们进展到哪一步了？
From Biomarkers to Precision Medicine in Neurodegenerative Diseases: Where Are We?
作者信息
Tondo Giacomo, De Marchi Fabiola
机构信息
Neurology Unit, S. Andrea Hospital, Department of Translational Medicine, University of Piemonte Orientale, 13100 Vercelli, Italy.
Division of Neuroscience, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.
出版信息
J Clin Med. 2022 Aug 3;11(15):4515. doi: 10.3390/jcm11154515.
Abstract
The biomarkers era grew in the last two decades when several technical and methodological advances have improved the research in neurodegenerative diseases [...].
摘要
生物标志物时代在过去二十年中兴起，在此期间，多项技术和方法上的进展推动了神经退行性疾病的研究[...]。
相似文献
1
From Biomarkers to Precision Medicine in Neurodegenerative Diseases: Where Are We?
J Clin Med. 2022 Aug 3;11(15):4515. doi: 10.3390/jcm11154515.
2
The Emerging Role of Proteomics in Precision Medicine: Applications in Neurodegenerative Diseases and Neurotrauma.
Adv Exp Med Biol. 2017;1007:59-70. doi: 10.1007/978-3-319-60733-7_4.
3
Perspectives in fluid biomarkers in neurodegeneration from the 2019 biomarkers in neurodegenerative diseases course-a joint PhD student course at University College London and University of Gothenburg.
Alzheimers Res Ther. 2020 Feb 28;12(1):20. doi: 10.1186/s13195-020-00586-6.
4
Implication of Electrophysiological Biomarkers in Psychosis: Focusing on Diagnosis and Treatment Response.
J Pers Med. 2022 Jan 2;12(1):31. doi: 10.3390/jpm12010031.
5
Precision Transplant Medicine: Biomarkers to the Rescue.
J Am Soc Nephrol. 2018 Jan;29(1):24-34. doi: 10.1681/ASN.2017010004. Epub 2017 Oct 9.
6
Personalized Nursing Care in Precision-Medicine Era.
SAGE Open Nurs. 2021 Dec 9;7:23779608211064713. doi: 10.1177/23779608211064713. eCollection 2021 Jan-Dec.
7
Conceptual endophenotypes: A strategy to advance the impact of psychoneuroendocrinology in precision medicine.
Psychoneuroendocrinology. 2018 Mar;89:147-160. doi: 10.1016/j.psyneuen.2017.12.009. Epub 2018 Jan 9.
8
Biomarkers in Search of Precision Medicine in IBD.
Am J Gastroenterol. 2016 Dec;111(12):1682-1690. doi: 10.1038/ajg.2016.441. Epub 2016 Sep 27.
9
The neuroinflammatory biomarker YKL-40 for neurodegenerative diseases: advances in development.
Expert Rev Proteomics. 2019 Jul;16(7):593-600. doi: 10.1080/14789450.2019.1628643. Epub 2019 Jun 14.
10
A Precision Medicine Initiative for Alzheimer's disease: the road ahead to biomarker-guided integrative disease modeling.
Climacteric. 2017 Apr;20(2):107-118. doi: 10.1080/13697137.2017.1287866. Epub 2017 Feb 9.
引用本文的文献
1
Neutrophil-to-Lymphocyte Ratio in the Alzheimer's Disease Continuum.
Int J Mol Sci. 2025 May 28;26(11):5157. doi: 10.3390/ijms26115157.
2
A novel muscle network approach for objective assessment and profiling of bulbar involvement in ALS.
Front Neurosci. 2025 Jan 10;18:1491997. doi: 10.3389/fnins.2024.1491997. eCollection 2024.
3
Exploration of Novel Biomarkers for Neurodegenerative Diseases Using Proteomic Analysis and Ligand-Binding Assays.
Biomedicines. 2024 Dec 9;12(12):2794. doi: 10.3390/biomedicines12122794.
4
Novel Therapeutic Strategies in Alzheimer's Disease: Pitfalls and Challenges of Anti-Amyloid Therapies and Beyond.
J Clin Med. 2024 May 25;13(11):3098. doi: 10.3390/jcm13113098.
5
From Recognition to Remedy: The Significance of Biomarkers in Neurodegenerative Disease Pathology.
Int J Mol Sci. 2023 Nov 9;24(22):16119. doi: 10.3390/ijms242216119.
6
Mitochondrial Dynamics in Neurodegenerative Diseases: Unraveling the Role of Fusion and Fission Processes.
Int J Mol Sci. 2023 Aug 22;24(17):13033. doi: 10.3390/ijms241713033.
7
Neuroinflammatory Pathways in the ALS-FTD Continuum: A Focus on Genetic Variants.
Genes (Basel). 2023 Aug 21;14(8):1658. doi: 10.3390/genes14081658.
8
Investigating the Prognostic Role of Peripheral Inflammatory Markers in Mild Cognitive Impairment.
J Clin Med. 2023 Jun 27;12(13):4298. doi: 10.3390/jcm12134298.
9
Neurology beyond big data - the ninth Congress of the EAN.
Nat Rev Neurol. 2023 Aug;19(8):445-446. doi: 10.1038/s41582-023-00837-8.
10
Emerging Trends in the Field of Inflammation and Proteinopathy in ALS/FTD Spectrum Disorder.
Biomedicines. 2023 May 31;11(6):1599. doi: 10.3390/biomedicines11061599.
本文引用的文献
1
Brain Metabolism and Amyloid Load in Individuals With Subjective Cognitive Decline or Pre-Mild Cognitive Impairment.
Neurology. 2022 Jul 18;99(3):e258-e269. doi: 10.1212/WNL.0000000000200351.
2
The Role of Tau beyond Alzheimer's Disease: A Narrative Review.
Biomedicines. 2022 Mar 24;10(4):760. doi: 10.3390/biomedicines10040760.
3
Cerebrospinal Fluid Biomarkers in Autopsy-Confirmed Alzheimer Disease and Frontotemporal Lobar Degeneration.
Neurology. 2022 Mar 15;98(11):e1137-e1150. doi: 10.1212/WNL.0000000000200040. Epub 2022 Feb 16.
4
Association of CSF, Plasma, and Imaging Markers of Neurodegeneration With Clinical Progression in People With Subjective Cognitive Decline.
Neurology. 2022 Mar 29;98(13):e1315-e1326. doi: 10.1212/WNL.0000000000200035. Epub 2022 Feb 2.
5
Plasma and CSF Neurofilament Light Chain in Amyotrophic Lateral Sclerosis: A Cross-Sectional and Longitudinal Study.
Front Aging Neurosci. 2021 Oct 22;13:753242. doi: 10.3389/fnagi.2021.753242. eCollection 2021.
6
Interplay between immunity and amyotrophic lateral sclerosis: Clinical impact.
Neurosci Biobehav Rev. 2021 Aug;127:958-978. doi: 10.1016/j.neubiorev.2021.06.027. Epub 2021 Jun 19.
7
Biomarkers for neurodegenerative diseases.
Nat Med. 2021 Jun;27(6):954-963. doi: 10.1038/s41591-021-01382-x. Epub 2021 Jun 3.
8
Plasma markers predict changes in amyloid, tau, atrophy and cognition in non-demented subjects.
Brain. 2021 Oct 22;144(9):2826-2836. doi: 10.1093/brain/awab163.
9
Comparison of Simoa and Ella to assess serum neurofilament-light chain in multiple sclerosis.
Ann Clin Transl Neurol. 2021 May;8(5):1141-1150. doi: 10.1002/acn3.51355. Epub 2021 Apr 8.
10
C-PK11195 PET-based molecular study of microglia activation in SOD1 amyotrophic lateral sclerosis.
Ann Clin Transl Neurol. 2020 Sep;7(9):1513-1523. doi: 10.1002/acn3.51112. Epub 2020 Aug 6.
Zotero 插件